Study Group AIDS-therapy
c/o Felix de Fries
Eglistr. 7 CH-8004 Zürich
Tel. /Fax: 0041 (0)44 401 34 24

Zurich, 24th November 2006
The Failure of HAART (Highly Active Antiretroviral Therapy)

The 5 August issue of the leading medical journal, The Lancet, presented the findings of a multicenter study on the effects of HAART treatment on 20,000 AIDS patients who had not been previously treated with chemotherapeutics, carried out between 1995 and 2003 at 12 locations in Europe and the USA. (Annex 1 / Annex 2)

The findings show that HAART treatment, since its introduction, has led to no sustained improvement in CD4 values, no reduction in AIDS-defining diseases and no reduction in mortality rates but that it has resulted in cardiovascular diseases, lipodystrophy, lactacidosis, liver and kidney failures, osteoporosis, thyroid dysfunctions, neuropathy, Parkinson’s disease and non AIDS-specific classes of cancer ( Annex 5 ).

Additionally, in a study appearing in the 27 September issue of the Journal of the American Medical Association, Beningo Rodriguez et al. pointed out that the numbers of CD4 cells measured in plasma and the amounts of so-called HIV-RNA (viral load) had no influence on disease progression and provided no practical information about the defence capacity and disease progression which were clearly determined centrally by “non-viral factors”. Thus, it is evident that the 1995 theory of Ho and Wey about the role of the so-called viral load in the pathogenesis of AIDS, on which HAART treatment is based, is not applicable ( see Annex 3 / Annex 4 ).

After a short period of time, HAART treatment led to the increased formation of precisely those opportunistic infections (from fungal infections of the lungs, skin and intestines via threadworms to various mycobacterial infections) that define the AIDS syndrome. The short-term rise in the CD4 cell count in plasma, resulting from this treatment, and the reduction in the so-called viral load were glossed over and attributed to a so-called “immune recovery syndrome” ( see Annex 6 ).

On the introduction of HAART treatment in 1995 the specialists had already predicted that the chemical attack by nucleoside analogs and protease inhibitors would lead to overreacting counterregulations in the immune system and chaos amongst the messenger substances as well as serious organ damage and not to a reduction in immune weakness and opportunistic infections. At that time the mass media were quick to report the great success of this therapy whereupon all the traceable “HIV positives” were emphatically urged by their doctors to begin this promising new therapy and to participate in a study.

The adverse results of HAART in the multicenter study were qualified in the Lancet article by stating that the composition of the test groups had changed as there were now more TB patients who had emigrated from developing countries.

This argumentation does not lack a certain irony. The HIV/AIDS model was thereby made conclusive in that a multitude of very diverse, well-known diseases such as TB, Malaria and all kinds of intracellular bacterial and fungal infections, chronic diarrhoea and degenerative events in lymph cells,  that occur with an advanced impairment of cellular immunity could be defined as AIDS after a positive result in the HIV antibody test. In the early 1980s, the inventors of the HIV antibody test adjusted it in such a way that most of the patients with these diseases were caught within its parameters. As a result of these self-affirming models, a sexually transmitted so-called human immunodeficiency retrovirus was taken to be the cause of all these infectious diseases and degenerative events and the antibodies, cell particles and proteases associated with the diseases were then termed as HIV antibodies, HIV cell particles and HIV proteases, without demonstrating this retrovirus according to the strict rules of virus isolation to be a transmittable infectious agent. After that it was no longer an issue that African and Asian AIDS patients suffer from very different diseases to those of European or US American AIDS patients (Annex 7 )

After nucleoside monotherapy (1985-1995), now the second gen- medical human experiment with HAART (1995-2006) demonstrated that intracellular infections and degenerative events in the lymph cells could no be successfully treated for a longer period with nucleoside analogs, protease inhibitors or chemical antibiotics, because the afflicted cells could only be recognized and destroyed by immune cells ( Annex 8 )

This does not prevent the pharmaceutical industry, AIDS doctors and the various relief organizations from continuing their call for the dispensing of these seriously toxic substances to roughly 40 million HIV positives worldwide and from promising them new antiviral substances without serious side-effects. The failure of these therapies remains hushed up by the mass media.

The actual causes for the spreading of AIDS-defining diseases: under- and malnutrition in southern and eastern countries, continuous re-infection through contaminated water supplies and wounds, the increasing poisoning of the environment through heavy metals nitrites, herbicides, pesticides and antibiotics, that reach human beings via the food chain, all result in damage to cellular immunity and thus lead to an increase in infections by intracellular agents continue to be masked by the self-affirming HIV AIDS model. ( Annex 9 ).

An immune system-supporting therapy of these diseases through plant compounds that intercept signals responsible for the continuation of inflammatory processes and through amino acids and trace elements which are necessary for the activities of the immune systemd ( Annex 10 ) has not been brought to clinical tests as these compounds cannot be patented and thus do not promise great profits.

The fact that since the completion of the Human Genome Project there have been rapid shifts in paradigm, in which assumptions have to be changed on which the HIV hypothesis and the HIV antibody test were based, has been ignored by the media, the AIDS establishment and the pharmaceutical industry. They continue to believe in anti-retroviral chemotherapy and the large profits associated with it.

We continue to hope for a re-think in medical science and believe that this is now unavoidable.
Feel free to read the various studies on all the above mentioned topics that we have presented since 1989.)

Study Group AIDS-therapy,

Felix A. de Fries